A group of eight past chairs of the MD Anderson Cancer Center Faculty Senate have weighed into the controversy over leadership and morale at the Houston-based hospital.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
